Small peptide-modified nanostructured lipid carriers distribution and targeting to EGFR-overexpressing tumor in vivo

It is suggested that AEYLR-modified NLC could be considered as a promising targeted delivery system for combination cancer chemotherapy to improve therapeutic efficacy and to minimize adverse effects.